Re: {LONGTERMINVESTORS} Dabur ...Thread
12 views
Skip to first unread message
Rajesh Desai
May 2, 2013, 12:44:40 AM5/2/13
to longterminve...@googlegroups.com, DAILY REPORTS, library-of-eq...@googlegroups.com
Dabur India - NB
· Result is better than market estimates.
· Consolidated
Net Revenue grew by 12.3% YoY at Rs. 1531.1 crs and down by 6.1% QoQ
basis. Domestic business remained steady with 15% YoY revenue growth
driven by 11% volume growth & ~4% due to pricing/mix. Dabur’s
International Business continues to be a key growth driver, recording a
strong 11.6% growth during Q4FY13, where Namaste performance remained
under
pressure.
· EBITDA
was up by 21.6% YoY to Rs. 272.9 crs and flat QoQ. The margins were
17.8% in Q4FY13 as against 16.5% in Q4FY12 and 16.8% in Q3FY13. The
improvement in margin was led by a sharp improvement in gross margins,
coupled with decline in ad spends (down 90bps YoY).
· The
Adj. Net profit grew by 17.6% YoY to Rs. 200.6 crs in Q4FY13 and down
by 5% QoQ. The PAT margin was 13.1% in Q4FY13 as against 12.5% in Q4FY12
and 12.9% in Q3FY13. The PAT grew due to the jump in Other income by
21% YoY and decline of depreciation cost by 4% YoY. Though interest cost
and tax rate was up during the same quarter.
--
CA. Rajesh Desai
Rajesh Desai
Jun 15, 2013, 2:27:41 AM6/15/13
to longterminve...@googlegroups.com, DAILY REPORTS, library-of-eq...@googlegroups.com
The US Food and Drug Administration (FDA) has imposed an import alert on Dabur India’s two manufacturing facilities in Himachal Pradesh.
The alert was placed after unapproved products from these facilities were found in the US market. The products in question include Dabur’s Meswak toothpaste, manufactured at its Baddi facility, and fairness cream bleach, made at the company’s unit in Nalagarh, according to the import alert posted on the US regulator’s website.
Dabur India said the products “seem to be part of an unauthorised export by an independent trader, without any consent or knowledge” of the company and it had already taken up the matter with the FDA.
A company spokesperson claimed Dabur did not export these products from India to the US. “Indian companies regularly get such alerts from authorities in the US and other developed countries. Based on these alerts, we prepare a dossier and submit relevant information to the authorities within the stipulated time, after which these matters are resolved,” the spokesperson told Business Standard.
Dabur sells many leading brands in the US from its portfolio, including hair oil and shampoo under the Vatika and Amla brands. It also sells Meswak in the US. However, the company official clarified, most of these products, including Meswak, are sourced from Dubai. “The products have been detained in the US because the batches were manufactured in our facilities in India, which are not registered there,” the official said.
Revenue contribution from the US market to Dabur’s consolidated sales is insignificant, said the official. “It is a very small market for us and sales are insignificant in our total numbers.”
Dabur is the third Indian company to come under the US FDA scanner in a month. In May, the regulator placed an import alert on Wockhardt’s drug manufacturing facility in Waluj. Pharmaceutical company RPG Life Sciences received a warning letter for violations of norms at manufacturing units in Ankleshwar and Navi Mumbai. Ranbaxy had earlier pleaded guilty in the US for making fraudulent statements to the regulator to gain drug approvals. It also paid a penalty of $500 million to settle issues with the US Department of Justice.
RAISING THE RED FLAG
* US FDA imposes import alert on Dabur India’s Baddi and Nalagarh facilities in Himachal Pradesh
* Import alert based on detention of unapproved products in the US
* Detained products include Meswak toothpaste with pure extract of rare herb, fairness cream bleach and fairness cream bleach with Gulabari
* Dabur says products seem to be part of an unauthorised export
* Dabur ‘s leading brands in the US, including Vatika, Amla and Meswak, sourced from Dubai
--
CA. Rajesh Desai
The alert was placed after unapproved products from these facilities were found in the US market. The products in question include Dabur’s Meswak toothpaste, manufactured at its Baddi facility, and fairness cream bleach, made at the company’s unit in Nalagarh, according to the import alert posted on the US regulator’s website.
Dabur India said the products “seem to be part of an unauthorised export by an independent trader, without any consent or knowledge” of the company and it had already taken up the matter with the FDA.
A company spokesperson claimed Dabur did not export these products from India to the US. “Indian companies regularly get such alerts from authorities in the US and other developed countries. Based on these alerts, we prepare a dossier and submit relevant information to the authorities within the stipulated time, after which these matters are resolved,” the spokesperson told Business Standard.
Dabur sells many leading brands in the US from its portfolio, including hair oil and shampoo under the Vatika and Amla brands. It also sells Meswak in the US. However, the company official clarified, most of these products, including Meswak, are sourced from Dubai. “The products have been detained in the US because the batches were manufactured in our facilities in India, which are not registered there,” the official said.
Revenue contribution from the US market to Dabur’s consolidated sales is insignificant, said the official. “It is a very small market for us and sales are insignificant in our total numbers.”
Dabur is the third Indian company to come under the US FDA scanner in a month. In May, the regulator placed an import alert on Wockhardt’s drug manufacturing facility in Waluj. Pharmaceutical company RPG Life Sciences received a warning letter for violations of norms at manufacturing units in Ankleshwar and Navi Mumbai. Ranbaxy had earlier pleaded guilty in the US for making fraudulent statements to the regulator to gain drug approvals. It also paid a penalty of $500 million to settle issues with the US Department of Justice.
RAISING THE RED FLAG
* US FDA imposes import alert on Dabur India’s Baddi and Nalagarh facilities in Himachal Pradesh
* Import alert based on detention of unapproved products in the US
* Detained products include Meswak toothpaste with pure extract of rare herb, fairness cream bleach and fairness cream bleach with Gulabari
* Dabur says products seem to be part of an unauthorised export
* Dabur ‘s leading brands in the US, including Vatika, Amla and Meswak, sourced from Dubai
--
CA. Rajesh Desai
Rajesh Desai
Nov 21, 2013, 3:06:39 AM11/21/13
to LONGTERMINVESTORS, DAILY REPORTS, library-of-eq...@googlegroups.com
Dabur India, the country's leading natural personal care company, has launched a new range of shampoo and hair oil fortified with the goodness of Hibiscus, under the brand Vatika. The new products are Vatika Enriched Coconut oil with Hibiscus and Vatika Premium Naturals Shampoo with Hibiscus, Reetha and Olive Conditioning.
This is the first-ever range of hair care products in India that have been enriched with Hibiscus, traditionally known to be effective in combating hair loss and dandruff. Cine star Kajal Agarwal would be endorsing the new variant of Vatika Premium Naturals shampoo, while southern cine star Samantha Prabhu has been signed as the face of the new Vatika Enriched Coconut hair oil with Hibiscus.
--
CA. Rajesh Desai
Reply all
Reply to author
Forward
0 new messages